BBC Broadcasts Interview with Dr. Samuel Stupp, Founder of Arrowhead Portfolio Company, Nanotope, Inc.

PASADENA, Calif.--(BUSINESS WIRE)-- An interview with Dr. Sam Stupp, founder and scientific advisor to Nanotope, Inc., an Arrowhead (NASDAQ: ARWR) portfolio company, was broadcast by the BBC World Service on November 28, 2010. In the interview, Dr. Stupp describes and discusses the regenerative medicine platform being developed by Nanotope, as well as nanotechnology and regenerative medicine in general.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies, Nanotope, Inc. and Leonardo Biosystems, Inc.



CONTACT:

The Piacente Group
Brandi Floberg, 212-481-2050

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Technology  Nanotechnology  Health  Biotechnology  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”